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Activin/nodal-like TGF−β superfamily ligands signal through the type I receptors Alk4, Alk5, and Alk7, and are responsible for mediating a
number of essential processes in development. SB-431542, a chemical inhibitor of activin/nodal signaling, acts by specifically interfering with
type I receptors. Here, we use inhibitor-resistant mutant receptors to examine the efficacy and specificity of SB-431542 in Xenopus and zebrafish
embryos. Treatment with SB-431542 eliminates Smad2 phosphorylation in vivo and generates a phenotype very similar to those observed in
genetic mutants in the nodal signaling pathway. Inhibitor-resistant Alk4 efficiently rescues Smad2 signaling, developmental phenotype, and
marker gene expression after inhibitor treatment. This system was used to examine type I receptor specificity for several activin/nodal ligands. We
find that Alk4 can efficiently rescue signaling by a wide range of ligands, while Alk7 can only weakly rescue signaling by the same ligands. In
whole embryos, nodal signaling during gastrulation can be rescued with Alk4, but not Alk7, while Alk5 can only mediate signaling by ligands
expressed later in development. The combination of the ALK inhibitor SB-431542 with inhibitor-resistant ALKs provides a powerful set of tools
for examining nodal/activin signaling during embryogenesis.
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Signaling by the transforming growth factor β (TGF-β)
superfamily of ligands is responsible for regulating a wide range
of cellular processes, including proliferation, cell death,
differentiation, and development. TGF-β ligands signal by
binding to two distinct types of serine-threonine kinase
receptors, designated type I and type II. Ligand binding induces
phosphorylation of the type I receptor by the type II receptor,
which subsequently phosphorylates receptor-regulated Smad
proteins, allowing them to translocate to the nucleus and interact
with transcription factors to modulate downstream gene
expression (reviewed by Shi and Massague, 2003; Whitman,
1998).
The activin/nodal subset of TGF-β superfamily ligands
signals through the type I receptors Alk4, Alk5, and Alk7, which⁎ Corresponding author.
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doi:10.1016/j.ydbio.2006.03.050leads to phosphorylation of Smad2 and Smad3 (Carcamo et al.,
1994; Ryden et al., 1996). Members of this class include early
pattern regulators such as nodals as well as later regulators of
development and growth such as GDF8/myostatin and canonical
TGF-β. During early development, the proper spatiotemporal
expression of nodal ligands and the tight regulation of signaling
levels are essential for specification of mesendoderm and for
left–right patterning (Schier, 2003). In the frog, Alk4 appears to
be the type I receptor responsible for the early nodal signaling
required for proper patterning of the germ layers during
gastrulation as well as for left–right patterning during tailbud
stages. In the mouse, loss of Alk4 results in early and lethal
defects in egg cylinder organization and gastrulation (Chen et
al., 2004; Gu et al., 1998). In vitro evidence suggests that Alk7
may be able to respond to nodal signals in some contexts, but an
Alk7 knockout has no phenotype (Jornvall et al., 2004;
Reissmann et al., 2001). Alk5 seems to be responsible for later
developmental events, such as heart patterning and angiogenesis
(Charng et al., 1998; Larsson et al., 2001).
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analysis about the role of activin/nodal ligands and their
receptors in development, there are in many cases technical
limitations to the interpretation of this analysis. First, late
developmental phenotypes are often obscured by disruptions in
signaling during early development, and second, signaling
components can be partially or completely redundant, making
unclear the function of individual components. While tissue-
specific gene inactivation in the mouse using the Cre–lox
system has provided an approach to the first of these issues, it is
limited by the temporal and spatial resolution of gene
expression driven by available enhancers, does not easily
address the problem of functional redundancy, and is not
currently applicable to other embryological model organisms.
Chemical inhibitors, which are easily applied to anamniote
embryos, can be readily added and removed and can
simultaneously inactivate closely related and partially redun-
dant signaling components, providing a potentially useful
complement to tissue-specific gene inactivation in the study
of temporally specific roles of developmental signals.
A chemical inhibitor of activin/nodal signaling, SB-431542,
inhibits Alk5 kinase activity in vitro with an IC50 of 94 nM, and
also inhibits Alk4 and Alk7 with similar potency (Callahan et
al., 2002; Inman et al., 2002). Studies in cell culture have shown
that SB-431542 can inhibit both Smad2/3 phosphorylation and
downstream reporter gene expression (Callahan et al., 2002).
While inhibitors like SB-431542 are potentially useful probes of
activin/nodal signaling function during embryogenesis, a major
concern about the use of such inhibitors is their specificity in
vivo. A molecule that is designed to bind in the active site of a
particular protein may also bind and affect other structurally
related but functionally distinct proteins. This is of particular
concern for small molecules targeted to ATP binding sites such
as SB-431542 (Callahan et al., 2002), since in vitro specificity
studies can never fully address the effect of the inhibitor on the
full range of nucleotide binding proteins present in vivo.
One means of demonstrating specificity is to show that an
inhibitor-resistant target can restore normal signaling and
phenotype in the presence of the inhibitor. Although such an
approach has not been used before in a complex in vivo system,
a mutant of the MAP kinase p38 that is resistant to the inhibitor
SB 203580 has been tested in tissue culture cells (Eyers et al.,
1998). SB-431542 has great potential as a tool to examine the
temporal requirements for nodal signaling throughout embryo-
genesis. To date, however, it has been used only in tissue culture
systems, and its efficacy and specificity in more complex in
vivo systems such as the early vertebrate embryo has not been
shown. We therefore examined the effect of SB-431542
treatment in Xenopus and zebrafish embryos. We show that
treatment with SB-431542 can eliminate both exogenously
stimulated and endogenous Smad2 phosphorylation and gen-
erates phenotypes strongly resembling those of known
perturbations in the nodal signaling pathway. To establish the
specificity of SB-431542 action, we constructed a point mutant
of Alk4 that is resistant to SB-431542 inhibition. This mutant
receptor efficiently rescues Smad2 signaling, developmental
phenotype, and marker gene expression in Xenopus andzebrafish upon treatment with SB-431542, demonstrating that
the effects of inhibition are indeed specific.
Finally, we used this inhibitor/receptor rescue system in
order to determine type I receptor specificity for a number of
important ligands and developmental processes. Mutant Alk4 is
able to mediate signaling for all ligands tested in Xenopus
animal cap explants, but mutant Alk7 can only weakly rescue
signaling by the same ligands. The competence of Alk5 to
mediate Smad2 signaling appears to be restricted to those
ligands acting later in development, such as GDF11 and GDF8/
myostatin. In support of these results, we also find that mutant
Alk5 is sufficient to rescue p-Smad2 signaling during tailbud
but not gastrula stages. Furthermore, while Alk4 can efficiently
restore signaling during gastrulation, an equal dose of Alk7
cannot, indicating that Alk7 is not an effective functional
substitute for Alk4 during early development.
Materials and methods
Plasmid construction
The Alk4 S275M mutant was generated using a one-step site-directed
mutagenesis protocol (Makarova et al., 2000). A single oligonucleotide primer
was designed incorporating the point mutation and flanking sequences. The
primer sequence (mutations in bold) was 5′-ACC CAG TTG TGG CTT GTT
ATG GAC TAT CAT GAG CAT GGA TCG-3′. A single-strand PCR reaction
was performed using pSP64T-xAlk4 WT as a template. Template was then
specifically degraded using DpnI (New England Biolabs). The DpnI-treated
PCR product was transformed into DH5α-competent cells, and colonies were
screened by sequencing for incorporation of the mutation. Alk4-GR constructs
were generated by subcloning PCR products encoding the open reading frame of
Alk4 S275M or WT upstream of codons 512–777 of the human glucocorticoid
receptor. HA-tagged Alk4 S275M and WT were made by PCR cloning the
coding region of Alk4 with the following primers (HA tag sequence in bold): up:
5′-AGA ATT CAT GGC GGA GCT ACC G-3′; down: 5′-TCA TGC ATA
ATC TGG TAC ATC ATA TGG ATA GAT TTT CAC ATC TTC-3′. The
PCR product was subcloned into pCS4+.
HA-tagged Alk5 S278M and Alk7 S270Mwere made using the mutagenesis
protocol above on wild-type parent plasmids pCS2-rAlk5-HA and pCS2-rAlk7-
HA. The primer for Alk5 S278Mwas 5′-ACT CAG CTG TGG TTGGTGATG
GAT TAT CAT GAG CAT GGATCC C-3′. The primer for Alk7 S270Mwas 5′-
GAC TCA GCT TTG GCT TGT GAT GGA GTATCA CGA GCA GGG C-3′.
Constitutively active Alks (Alk* constructs) were made by introducing T to
D mutations using the following primers: xAlk4* (T199D): 5′-CAG CGG ACT
GTG GCG AGA GAT ATC GTG CTA CAA GAA AGC ATC G-3′; rAlk5*
(T202D): 5′-GTT CAA AGA ACA ATT GCA AGG GAT ATC GTG CAT
CAA GAA AGC ATC G-3′; rAlk7* (T194D): 5′-CAA AGA ACC ATC GCA
AGG GAT ATC GTA CTT CAA GAA ATC GTA GGA-3′.
Constructs in pSP64T were linearized with EcoRI, and constructs in pCS
vectors were linearized with NotI. mRNAs were transcribed with SP6 RNA
polymerase using the mMessage mMachine kit (Ambion).
Xenopus embryo manipulation
Xenopus embryos were fertilized and maintained as previously described
(Watanabe and Whitman, 1999). Embryos were staged according to Nieuwkoop
and Faber (1967). For animal cap experiments, embryos were injected animally
at the 2-cell stage with 10 nl of mRNA in each blastomere. For whole embryo
experiments, embryos were injected marginally at 2- to 4-cell stage. For Alk4-
GR injections, embryos were injected twice on one side at the 4-cell stage along
with GFP mRNA as a tracer, and sorted into left and right side injected embryos
based on GFP fluorescence at stage 22 prior to fixation.
Animal cap dissections were performed between stages 8 and 9, and explants
were maintained in 0.7× MMR in agarose-coated dishes. For activin protein
Fig. 1. SB-431542 reversibly blocks phospho-Smad2 in Xenopus animal cap
explants and zebrafish embryos. Western blots for p-Smad2 were performed on
(A) Xenopus animal caps treated with 100 μM SB-431542 or DMSO followed
by 0.3 nM soluble activin protein, (B) 50% epiboly zebrafish embryos treated
with 100 μM SB-431542 or DMSO at 16-cell stage, and (C) tails from stage 34
embryos treated with 100 μM SB-431542 or DMSO at stage 19 for 24 h and
either washed (lane 1) or unwashed (lanes 2 and 3) for 16 h. Cytoskeletal actin
was used as a loading control.
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431542 (Tocris) or DMSO for 45 min to 1 h followed by treatment with 0.3–
2 nM activin protein in 0.1% BSA and 0.02% gelatin for 45 min to 1 h, and
harvested immediately afterward for Western blotting. For Alk4-GR experi-
ments, embryos were treated with 10 μM dexamethasone (Sigma) 1 h prior to
treatment with SB-431542. For injected ligand experiments, animal caps were
incubated overnight at 14°C in 100 μM SB-431542 or DMSO before harvesting
at stages 10–10.5.
Zebrafish embryo manipulation
Adult wild-type zebrafish of the AB strain were maintained and embryos
collected as previously described (Chan et al., 2001). Embryos were maintained
at 24°–33°C and staged according to Kimmel et al. (1995).
For injections, stock mRNA solutions were diluted to working concentra-
tions in 1× Danieau's solution (58 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO4,
0.6 mM Ca (NO3)2, 5 mM HEPES, pH 7.6) with 0.1% phenol red. Embryos
were injected in the yolk at the one cell stage with approximately 2 nl of working
concentration mRNA.
Embryos were treated with SB-431542 or DMSO at the 16-cell stage unless
otherwise noted. SB-431542 was added to a final concentration of 100 μM from
stocks of 20 to 100 mM in 80–100%DMSO; DMSOwas added to all controls at
an equivalent final dilution.
Live embryos were photographed in 2% methylcellulose (Sigma) using a
Leica MZFLIII stereomicroscope, Optronics camera, and Magnafire software.
In some cases, color balance and contrast were slightly adjusted with Adobe
Photoshop 7.
Western blotting
Xenopus animal caps and zebrafish embryos were lysed for Western blotting
in modified RIPA buffer (Yeo and Whitman, 2001). 2–2.5 animal caps or 1–1.5
zebrafish embryos were loaded per lane. P-Smad2 antibodies have been
described previously (Faure et al., 2000); here, the acid eluate was used at a
dilution of 1:100–1:200. For tissue culture cells, commercially available p-
Smad2 antibody (Cell Signaling Technologies) was used at a dilution of 1:500.
Cytoskeletal actin (AC-40, Sigma) and tubulin (DM1, Sigma) were used as
loading controls.
In situ hybridization
Whole-mount in situ hybridization on zebrafish and Xenopus embryos was
performed as described previously (Chan et al., 2001; Harland, 1991).Results
SB-431542 effectively blocks exogenous and endogenous
p-Smad2 signaling in embryos
SB-431542 has been shown to block phospho-Smad2 (p-
Smad2) signaling downstream of the type I receptors Alk4,
Alk5, and Alk7 in tissue culture, but its efficacy in vivo has not
been determined (Callahan et al., 2002; Inman et al., 2002).
Therefore, we tested whether SB-431542 could attenuate both
endogenous and exogenously induced Smad2 phosphorylation
in the vertebrate embryo. Treatment with activin protein induces
Smad2 phosphorylation in Xenopus animal cap explants; this
induction is completely blocked by addition of 100 μM SB-
431542 (Fig. 1A). Although doses of SB-431542 as low as
10 μM could block the majority of p-Smad2 signaling in animal
caps (data not shown), we have used 100 μM throughout this
study since this higher dose was required to elicit p-Smad2
block and phenotypic alterations in whole embryos (see below).Endogenous p-Smad2 in zebrafish embryos at 50% epiboly
is eliminated upon treatment with 100 μM SB-431542 (Fig.
1B). At least 50 μMSB-431542 is required in whole embryos to
cause complete block of p-Smad2 and phenotypic alteration;
this is approximately 5- to 10-fold more than the concentration
required in animal caps and in vitro (Inman et al., 2002). This
relatively high dose requirement may reflect the additional
complexities of tissue thickness, permeability, and drug efflux
pumps in intact embryos.
We also tested whether the effect of SB-431542 could be
reversed after removal of the inhibitor. Xenopus embryos treated
with SB-431542 were washed out and allowed to recover in
inhibitor-free media for 16 h; this treatment allowed p-Smad2 in
the tailbud of these embryos to recover to levels comparable to
the DMSO-treated control, indicating that SB-431542 treatment
is indeed reversible (Fig. 1C).
Phenotypic consequences of SB-431542 treatment in embryos
In intact Xenopus embryos, early SB-431542 treatment
blocks endogenous p-Smad2 and causes failure of blastopore lip
formation at stage 10 and abnormal, incomplete gastrulation
(Figs. 2A and B and data not shown). This phenotype is very
similar to that caused by overexpression of known inhibitors of
nodal signaling (Agius et al., 1999; Onuma et al., 2002).
Treatment of Xenopus embryos at a later, post-gastrulation stage
(stage 13) altered left–right patterning as assessed by expression
Fig. 2. SB-431542 induces morphological defects in embryos. (A–B) Xenopus embryos were treated with SB-431542 (A) or DMSO (B) at stage 3 and allowed to
develop until stage 11. Note failure of blastopore lip formation in the treated embryo. (C–D) Xenopus embryos were treated with SB-431542 (C) or DMSO (D) at stage
13 and fixed for in situ hybridization with an xAntivin antisense probe at stage 22. Embryos are photographed with anterior to the left and the left side showing. Note
loss of left-sided xAntivin expression (red arrow in panel D) in the treated embryo. (E–I) Zebrafish embryos were treated with 100 μMSB-431542 or DMSO at 16-cell
stage and examined at 24 hpf. (E) SB-431542-treated embryo, displaying head and midline defects, fewer and more posterior somites, and poor yolk extension
morphology. (F) Close-up of head region of SB-431542-treated embryo with “severe” phenotype. (G) Close-up of head region of SB-431542-treated embryo with
“moderate” phenotype. (H) DMSO-treated control embryo. (I) Close-up of head region of control embryo. (J–L) Embryos treated at 16-cell (J) have more severe loss
of head and axial structures (arrows) than those treated at 256-cell (K), although both are significantly perturbed compared to controls (L).
Table 1
Head phenotypes of 24 hpf embryos treated with 100 μM SB-431542
Normal (WT) Moderate Severe
100 pg Alk4 S275M +SB 36/65 (55%) 17/65 (26%) 12/65 (18%)
100 pg Alk4 S275M +DMSO 71/78 (91%) 7/78 (9%) 0/78 (0%)
100 pg Alk4 WT +SB 4/84 (5%) 32/84 (38%) 48/84 (57%)
100 pg Alk4 WT +DMSO 88/88 (100%) 0/88 (0%) 0/88 (0%)
Uninjected +SB 5/51 (10%) 19/51 (37%) 27/51 (53%)
Uninjected +DMSO 45/45 (100%) 0/45 (0%) 0/45 (0%)
(Results are combined from 3 separate experiments).
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and D). Additionally, gut origin and coiling were randomized in
embryos treated with SB-431542 from stages 19 to 25 (data not
shown).
Zebrafish embryos treated with SB-431542 early in
development display reproducible phenotypic alterations con-
sistent with loss of nodal signaling. At 24 h post-fertilization
(hpf), treated embryos show significant morphological pertur-
bations, including severe head and midline defects, fewer and
more posteriorly restricted somites, and poor separation and
elongation of the yolk extension (Figs. 2E and H). The anterior
defects are particularly striking, and range in severity from
moderate (some structures deformed or fused, but still
recognizable) to severe (no visually identifiable structures)
(Figs. 2F, G, and I). This phenotype was highly penetrant, with
90% of embryos showing significant anterior defects (Table 1).
The severity of the phenotype depends upon the stage at which
SB-431542 is added. Embryos treated at 16-cell stage (Fig. 2J)demonstrate greater loss of anterior structures than those treated
at 256-cell stage (Fig. 2K).
In situ hybridization experiments were performed to examine
the expression patterns of marker genes at various timepoints
after inhibitor treatment. Nodal signaling is important for
establishing mesodermal cell fates, particularly dorsally (Dou-
gan et al., 2003). Therefore, we examined the expression of
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the dorsal mesodermal marker goosecoid (gsc) at shield stage is
completely abrogated or severely reduced in SB-431542-treated
embryos (Figs. 3A and B). Expression of the pan-mesodermal
marker no tail/brachyury (ntl) is excluded from the dorsal
marginal region, while ventrolateral expression of these genes
remains unaffected (Figs. 3C and D). In contrast, SB-431542
treatment had no effect on the ventral mesodermal marker even-
skipped1 (eve1) (Figs. 3E and F).
We also examined the expression of several later marker
genes known to be affected by nodal signaling. At the end of
gastrulation (bud stage), presumptive notochord staining of ntl
was absent in treated embryos, although the tailbud expression
domain remained (Figs. 3G and H). Expression of the floorplate
marker sonic hedgehog (shh) and the notochord marker axial
were also absent in SB-431542-treated embryos (arrows in Figs.
3I and J, and data not shown). Shh expression continued to be
severely reduced, with virtually no staining in the anterior part
of the embryo and occasional weak, discontinuous staining in
the posterior, at the 18-somite stage (Figs. 3K and L).Fig. 3. SB-431542 treatment alters marker gene expression in zebrafish embryos. E
harvested for in situ hybridization with (A, B) goosecoid (gsc), (C, D) no tail (ntl), a
pax2.1 at bud stage, and (K, L) shh at 18-somite stage. Gsc expression in the dorsal
embryos. In control embryos, ntl expression forms a ring around the margin (D), b
contrast, eve1 expression is not affected (E, F). At bud stage, ntl expression in the tai
(arrows in panels I and J) expression is also lost in the presumptive notochord / floor
somite stage, shh expression is still severely reduced, with virtually no signal in th
discontinuous staining in the posterior (arrowheads in panel K). Shield stage em
embryos (G–J) are photographed with the anterior to the top.The phenotype of SB-431542-treated embryos bears a
striking resemblance to those of several genetic mutants in the
nodal signaling pathway, specifically cyclops/squint (cyc;sqt)
and one-eyed-pinhead (Mzoep) (Feldman et al., 1998; Gritsman
et al., 1999). In addition to the severe disruption of dorsal
mesodermal markers and dorso-anterior mesodermal structures
(Figs. 2 and 3), we also observe abnormal thickening in the
dorsal–medial region of late gastrula embryo (data not shown),
which has been attributed to abnormal epiboly and convergence
movements in Mzoep mutants (Gritsman et al., 1999).
Significantly, general anterior–posterior (A–P) patterning of
the neural plate did not appear to be affected, as A–P
localization of Pax2.1 and Krox20 appeared normal (arrow-
heads in Figs. 3G–J, and data not shown), a result also observed
in MZoep mutant embryos (Feldman et al., 1998; Gritsman et
al., 1999). Taken together, these data suggest that SB-431542 is
indeed functioning by specifically downregulating nodal
signaling in the early embryo. In the frog, nodal signaling
during early embryogenesis is mediated by the type I receptor
Alk4 (Chang et al., 1997). The zebrafish type I receptormbryos were treated with 100 μM SB-431542 or DMSO at 16-cell stage, and
nd (E, F) even-skipped-1 (eve1) at shield stage, (G, H) ntl, (I, J) axial, and (I, J)
organizer region embryos is severely reduced in treated (A) versus control (B)
ut expression on the dorsal side is lost in SB-431542-treated embryos (C). In
lbud (arrow) is normal, but notochord signal (arrowhead) is absent (G, H). Axial
plate. Pax2.1 expression is unaffected (arrowheads in panels I and J). By the 18-
e anterior of the embryo (compare panel K to arrow in panel L), and weak,
bryos (A–F) are photographed with the dorsal side to the right. Bud stage
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receptor that transduces the early nodal signal in fish (Aoki et
al., 2002; Renucci et al., 1996).
Generation of a mutant Alk4 that is insensitive to SB-431542
inhibition
To establish the specificity of the inhibitor, we devised a
strategy for rescuing SB-431542-treated embryos using an
inhibitor-insensitive Alk4. A mutant receptor that is resistant to
the p38 inhibitor SB 203580 has been described. Mutation of
Thr106 in the ATP-binding pocket of p38 to Met renders it
insensitive to inhibition by SB203580; the size of this residue
appears to be crucial in determining inhibition efficiency (Eyers
et al., 1998). The equivalent residue in the ATP-binding sites of
Alk4, Alk5, and Alk7 is a small, conserved serine, suggesting
that the inhibitor should bind the wild-type receptor efficiently.
Since SB 203580 and SB-431542 are structurally similar, it is
likely that their mechanisms of inhibition will also be the same
(Callahan et al., 2002). Therefore, using the p38 mutant as a
paradigm, we generated a point mutant of Alk4 (Alk4 S275M) in
which this serine residue was changed to a large, hydrophobic
methionine.
We examined whether Alk4 S275M could restore p-Smad2
signaling in inhibitor-treated animal caps and embryos.
Xenopus animal cap explants injected with 100 pg of Alk4
S275M showed phosphorylation of Smad2 upon activin
treatment, even in the presence of 100 μM SB-431542, where-
as those injected with wild-type Alk4 (Alk4 WT) did not
(Fig. 4A). Alk4 S275M did not ectopically activate Smad2Fig. 4. Alk4 S275M restores phospho-Smad2 signaling to SB-431542-treated
animal caps and embryos. Embryos (Xenopus and zebrafish) were injected with
100 pg Alk4 S275M or 100 pg Alk4 WT. Western blots for phospho-Smad2
were performed on (A) stage 8.5 Xenopus animal caps treated with 100 μM SB-
431542 or DMSO followed by 2 nM soluble activin protein, and (B) 50%
epiboly zebrafish embryos treated with 100 μM SB-431542 at 16-cell stage.
Cytoskeletal actin and tubulin were used as loading controls for panels A and B,
respectively.signaling in the absence of activin, indicating that, at these
doses, the mutant receptor does not non-specifically or
constitutively activate the Nodal pathway to an appreciable
level in animal caps. Similarly, Alk4 S275M but not Alk4 WT
rescued endogenous p-Smad2 in SB-431542-treated zebrafish
embryos at 50% epiboly (Fig. 4B).
Alk4 S275M rescues phenotypic and gene expression defects in
SB-431542-treated zebrafish embryos
Since Alk4 S275M could restore p-Smad2 signaling in
embryos, we used it to ask whether the SB-431542-induced
phenotype of embryos was likewise specific. Alk4 S275M did
indeed rescue the SB-431542 phenotype in zebrafish. 55%
(n = 65) of embryos injected with 100 pg Alk4 S275M mRNA
and subsequently treated with 100 μM SB-431542 displayed
phenotypically normal head development (Table 1). Rescued
embryos had two distinct and separate eyes and normal midline
structures (Fig. 5A). The unrescued fraction of embryos
probably reflects poor or incomplete dispersal of the injected
mRNA throughout the entire embryo. In contrast to Alk4
S275M, wild-type Alk4 was unable to rescue inhibitor-induced
head defects (Table 1; Fig. 5C). Embryos injected with mRNA
encoding either wild type or mutant receptors and treated with
DMSO were phenotypically indistinguishable from uninjected
embryos, indicating that the receptors alone do not significantly
affect phenotype (Figs. 5B and D). A lower dose (50 pg) of
mRNA was still able to rescue, but was less efficient (data not
shown). Neither mutant Alk5 nor mutant Alk7 were able to
rescue SB-431542-induced defects at doses of up to 200 pg
mRNA (data not shown).
Mesodermal marker gene expression was also rescued by
Alk4 S275M. Whereas SB-431542-treated Alk4 WT embryos
showed little or no gsc at shield stage, expression was restored
in Alk4 S275M embryos (Figs. 6A–D). Similarly, ntl
expression in the dorsal margin was present in SB-431542-
treated Alk4 S275M embryos but not in Alk4 WT embryos
(data not shown). The notochord expression domain of ntl was
restored in SB-431542-treated Alk4 S275M embryos, but not in
Alk4 WT embryos (Figs. 6E–H) Midline expression of shh and
axial at bud stage in treated embryos could also be rescued by
injection of Alk4 S275M (data not shown). At the 18-somite
stage, the full range of expression of shh, including the anterior-
most domain, was restored by Alk4 S275M but not by Alk4 WT
(Figs. 6I–L).
Alk4 S275M rescues phenotypic and gene expression defects in
SB-431542-treated Xenopus embryos
In Xenopus embryos treated with SB-431542 before
gastrulation, we found that expression of Alk4 S275M rescues
blastopore lip formation (data not shown). We also observed,
however, that doses of Alk4 mRNA necessary for rescue of
blastopore lip formation in Xenopus cause additional, inhibitor-
independent defects in post-gastrula patterning. This observa-
tion suggests that ectopic Alk4 expression may be sufficient to
alter nodal signaling patterns in Xenopus embryos. A previous
Fig. 5. Alk4 S275M rescues the SB-431542-induced phenotype in zebrafish
embryos. Zebrafish embryos were injected with (A, B) 100 pg Alk4 S275M or
(C, D) 100 pg Alk4 WT, treated with 100 μM SB-431542 or DMSO at 16-cell
stage, and photographed at 24 hpf. Alk4 WT embryos display severe anterior
defects (C) when treated with SB-431542, but Alk4 S275M embryos appear
wild-type (A). DMSO-treated controls (B, C) appear normal, indicating that
injection of the receptors alone does not affect morphology.
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Alk4 injection alone (Chang et al., 1997), consistent with this
possibility. We believe that this may be because embryos are
exquisitely sensitive to levels of nodal signaling during
gastrulation, and that additional Alk4 may lead to excessive
signaling by endogenous ligands. Alternatively, the receptor
itself may have ligand-independent activity that falls below the
threshold of detection on anti-pSmad2 Western blot, but is
nevertheless significant for patterning. Therefore, in order to use
mutant Alk4 to examine later processes such as left–right
patterning, we made a glucocorticoid receptor (GR) fusion of
Alk4 (Alk4-GR), which could be activated by addition of the
hormone dexamethasone (Dex) prior to inhibitor treatment but
after gastrulation (Kolm and Sive, 1995). Although function of
this fusion protein is not completely abolished by the GR
domain in the absence of Dex, it is suppressed enough such that
the embryos can undergo normal gastrulation at relevant doses
(M. Whitman and M. Watanabe, unpublished and data not
shown).
Left-sided injection of 150 pg of Alk4-GR S275M was
able to restore left-sided xAntivin expression in embryos
treated with SB-431542 (48%, n = 90) at stages 13–14,
while an equal dose of Alk4-GR WT could not (3%,
n = 36) (Table 2 and Fig. 7). Notably, the rescued xAntivin
expression was only seen in places where xAntivin is
normally expressed, although the injected mRNA was
present throughout the entire left side of the embryo (Fig.
7 and data not shown). We observed some right-sided
misexpression of xAntivin in embryos injected on the right
side with Alk4-GR S275M; this is probably caused by the
slight residual (Dex independent, possibly ligand indepen-
dent) activity of the Alk4-GR constructs earlier in
development (Table 2 and data not shown).Type I receptor specificity in Xenopus animal caps
Many activin/nodal ligands have been implicated in
embryonic patterning, including activin, nodals (Xnr1–6 in
Xenopus), Derriere, Vg1, GDF8/myostatin, GDF11 and canon-
ical TGF-βs (reviewed by Chang et al., 2002; Schier, 2003).
Three type I receptors, Alk4, Alk5, and Alk7, are thought to be
responsible for mediating the signal produced by these ligands.
Previous work on ligand/type I receptor specificity has relied on
indirect overexpression techniques, such as co-immunoprecip-
itation of tagged receptors in tissue culture systems. Our
inhibitor/receptor system allows for the selective restoration of a
single functional mutant type I receptor after SB-431542
treatment, thus enabling the identification of individual
functional ligand/receptor pairs in a systematic manner.
Xenopus animal caps express no endogenous nodal ligands,
so the only nodal signaling source is the introduced ligand of
interest. Since SB-431542 blocks signaling through all known
activin/nodal type I receptors (thus eliminating background
from endogenous receptors), only introduction of the correct
mutant receptor should restore signaling by a given ligand,
whereas receptors not compatible with this ligand would have
no effect.
To facilitate meaningful comparison between the three
receptors, we constructed HA-tagged forms of mutant and
wild-type Alk4, Alk5, and Alk7. In our experiments, tagged
Alk5 protein was 60- to 80-fold more efficiently expressed than
either Alk4 or Alk7 (Fig. 8A). Thus, in the experiment shown in
Fig. 8B, we injected 3 ng of Alk4, 50 pg of Alk5, and 4 ng of
Alk7, such that approximately equal protein levels were
obtained. (We have observed that tagged versions of the Alks
appear to be much less active than the corresponding untagged
constructs (data not shown), hence the apparent discrepancy
between the dose of Alk4-HA (3 ng) used here with the lower
doses of untagged Alk4 (50–150 pg) used in the experiments
described earlier).
Five activin/nodal ligands with developmental significance
were tested in our assay: ActivinβB, Xnr1, Derriere, GDF11,
and GDF8/myostatin. We found that Alk4 S275M was capable
of efficiently restoring signaling by all five ligands, whereas
Alk5 S278M could do so only for GDF11 and GDF8, albeit
weakly (Fig. 8B). Alk7 S270M partially rescued pSmad2
activation in response to all the ligands, but rescue by mutant
Alk7 was consistently much weaker than that seen with a
comparable dose of mutant Alk4 for all ligands tested (Fig. 8B).
In no case was any wild-type receptor able to restore signaling
in the presence of SB-431542 (Fig. 8B). Both high doses (1–
2 ng, which generate strong, easily photographed, and
completely regulated pSmad2 bands) and low doses (100–
200 pg, consistent with doses required for mesodermal
induction) of Xnr1, Derriere, GDF11, and GDF8 were tested
with the same results (Fig. 8B and data not shown).
One possible explanation for the observed differences in
rescue potency of different Alks is that the receptors have
different levels of intrinsic activity, rather than differences in
ability to utilize particular ligands. To address this possibility,
we generated constitutively active receptors (Alk*). The S to M
Fig. 6. Alk4 S275M rescues marker gene expression in SB-431542-treated embryos. Zebrafish embryos were injected with 50 pg Alk4 S275M or 50 pg Alk4 WT and
treated with 100 μMSB-431542 or DMSO at 16-cell stage. Embryos were harvested for in situ hybridization for gsc at shield stage (A–D, dorsal to the right), ntl at bud
stage (E–H, anterior to the top), and shh at 18 somite stage (I–L). Alk4 S275M restores gsc expression in SB-431542-treated embryos (A), whereas Alk4 WT did not
(C). Notochord expression of ntl at bud stage was restored in Alk4 S275M-injected embryos (arrow in panel E), but not in Alk4WTembryos (G). Similarly, expression
of shh, including anterior domains (arrows in panel I), was rescued in Alk4 S275M embryos (I), but not in Alk4 WT embryos (K). DMSO-treated embryos displayed
normal expression patterns for all genes examined (B, D, F, H, J, L).
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signaling efficiency for any of the constitutively active receptors
(data not shown). When we compared the activity of different
constitutively activated Alks at equal protein levels, we find that
Alk4* and Alk7* signal equally well. Surprisingly, however,
Alk5* is far less active than Alk4* or Alk7* in this system (Fig.Table 2
xAntivin expression at stages 22–23 in the flank of unilaterally injected Alk4GR em
Injected side Left
150 pg Alk4GR S275M +SB L 43 (48%)
150 pg Alk4GR S275M +SB R 2 (3%)
150 pg Alk4GR S275M +DMSO L 24 (69%)
150 pg Alk4GR S275M +DMSO R 12 (39%)
150 pg Alk4GR WT +SB L 1 (3%)
150 pg Alk4GR WT +SB R 0 (0%)
150 pg Alk4GR WT +DMSO L 31 (97%)
150 pg Alk4GR WT +DMSO R 22 (81%)
Uninjected +SB – 0 (0%)
Uninjected +DMSO – 30 (97%)
All embryos (except uninjected) were treated with 10 μM dexamethasone starting 1 h
into left- and right-side injected prior to fixation by localization of coinjected GFP.
Results are combined from 4 separate experiments (except for uninjected—2 experi8C). A 100-fold excess (5 ng) of Alk5* is required to approach
the activity of the other two receptors (Fig. 8C). (Because of
RNA toxicity issues, it was not feasible to increase the dose
further). Therefore, in order to correct for signaling efficiency,
we repeated the ligand rescue experiment with 5 ng Alk5
S278M or WT. This dose was still unable to elicit rescue ofbryos
Right Both None Total (n)
0 (0%) 1 (1%) 46 (51%) 90
19 (24%) 3 (4%) 55 (70%) 79
0 (0%) 1 (3%) 10 (29%) 35
9 (29%) 5 (16%) 5 (16%) 31
0 (0%) 0 (0%) 35 (97%) 36
0 (0%) 0 (0%) 23 (100%) 23
0 (0%) 0 (0%) 1 (3%) 32
0 (0%) 0 (0%) 5 (19%) 27
0 (0%) 0 (0%) 30 (100%) 30
0 (0%) 0 (0%) 1 (3%) 31
before treatment with 100 μM SB-431542 or DMSO at stages 13–14 and sorted
ments).
Fig. 7. Alk4 S275M rescues left–right patterning in SB-431542-treated Xenopus
embryos. Embryos were injected on the left side only with 150 pg xAlk4-GR
S275M (A, B) or xAlk4-GR WT (C, D) mRNA and treated with 10 μM
Dexamethasone at stage 13.5 followed by 100 μM SB-431542 (A, C) or DMSO
(B, D) at stage 14. Embryos were processed for in situ hybridization with an
xAntivin antisense probe at stage 22. Embryos were photographed with the
anterior to the left and the left side showing. Note specific recovery of antivin
expression (red arrow) in the left flank in panel A.
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GDF11 and GDF8 signaling, indicating that when intrinsic
signaling capacity of the receptors is corrected for, Alk5 is as
good a receptor as Alk4 for GDF11 and GDF8, but not for the
other ligands tested (Fig. 8D).
Type I receptor specificity in embryos
GDF11 and GDF8 are not expressed before or during
gastrulation, but are expressed later in development, suggesting
that Alk5 may specifically respond to later ligands. To test this
possibility, we asked whether mutant Alk5 could rescue
endogenous p-Smad2 signaling during either early or late
embryogenesis in SB-431542-treated Xenopus embryos. At
gastrulation (st. 10+), 3 ng of mutant Alk5 was unable to rescue
any detectable Smad2 phosphorylation in whole embryos (Fig.
8F). We also observed that blastopore lip formation was never
restored by Alk5 S278M in the presence of SB-431542, in
contrast to the rescue of lip formation observed with Alk4
S275M (data not shown). During early tailbud stages in
Xenopus, p-Smad2 signaling is observed in the tail and head
regions (D.M.H. and M.W., unpublished observations). In
contrast to what we observe during gastrulation, p-Smad2
signaling in the tailbud at stage 26 was blocked by SB-431542
and rescued efficiently by 3 ng of mutant Alk5 (Fig. 8F). The
same is true of p-Smad2 signaling in the head at this stage (data
not shown).
The experiments shown in Fig. 8B suggest that, although
they appear to have the same specificity, Alk4 rescues pSmad2
in response to all ligands tested more efficiently than Alk7 in
animal caps. It is possible that the reason for this apparent
difference in sensitivity is that mutant Alk7 is not completely
resistant to SB-431542. In order to rule out this possibility, we
asked whether Alk7* S270M could signal less well in the
presence of SB-431542. We find that this is not the case; bothAlk7* S270M and Alk4* S275M retain all of their signaling
capability even in the presence of SB-431542, indicating that
both mutants are equally and completely resistant to inhibition
(Fig. 9A). Thus, the decreased ability of Alk7 S270M to rescue
signaling relative to Alk4 S275M most likely reflects a true
difference in the ability of Alk7 to respond to ligands.
We next asked whether the relative potencies of Alk4 S275M
and Alk7 S270M in rescuing SB-431542 in animal caps were
recapitulated in whole embryos. High levels of p-Smad2
signaling are required during late blastula and gastrula stages
in Xenopus embryos (Lee et al., 2001). p-Smad2 in stage 10+
whole embryos was effectively blocked by SB-431542; this
signal could be rescued by mutant Alk4 but not an equivalent
dose of mutant Alk7 (Fig. 9B). Indeed, as little as 1.5 ng of Alk4
mRNAwas able to rescue signaling, while 6 ng of Alk7 mRNA
could not. Phenotypically, blastopore lip formation at stage 10+
was prevented by SB-431542 and rescued by Alk4 S275M but
not Alk7 S270M (Figs. 9C–J). Treated Alk4 S275M embryos
go on to form complete blastopore lips at stage 10.5,
concomitantly with untreated embryos, while SB-431542-
treated Alk7 embryos still have no discernible blastopore lip
(data not shown). In summary, these experiments demonstrate
that there is differential usage of type I receptors by particular
ligands and during specific developmental events, and suggest
that regulation of ligand/receptor pairing may be important
during embryogenesis.
Discussion
A rescuable inhibitor/receptor system for in vivo studies
In zebrafish and Xenopus, loss-of-function analyses are
generally carried out using genetic mutants, antisense oligos, or
dominant-negative constructs. All of these strategies, with the
exception of rare temperature-sensitive mutations, are difficult
or even impossible to regulate spatially or temporally.
Traditional methods are also insufficient for examining the
effects of transient versus sustained signaling during
embryogenesis.
Chemical inhibitors of signaling pathways, such as SB-
431542, in contrast, can be easily added or removed from media
at any time. We show here that SB-431542 is indeed effective as
a reversible inhibitor of endogenous and exogenous p-Smad2
signaling in early embryogenesis (Fig. 1). Furthermore,
phenotype and marker gene expression are altered in a manner
consistent with inhibition of nodal signaling (Figs. 2 and 3).
SB-431542 is a powerful tool for examining the temporal
requirements for activin/nodal signaling during development.
The relatively high concentration of inhibitor that is required
for penetration of embryos, and the additional complexities
of multiple cell types and pathways in an intact embryo,
however, increase the likelihood of off-target effects in
embryos relative to a monolayer of a single cultured cell
type. To demonstrate the specificity of inhibition of activin/
nodal signaling by SB-431542, we show that introduction of
an SB-431542-resistant mutant receptor rescues the inhibitor-
induced phenotype and can restore the expression of
Fig. 8. Alk4, Alk5, and Alk7 mediate signaling by different subsets of activin/nodal ligands (A) Embryos were injected with 3 ng Alk4-HA SM (4M), 50 pg Alk5-HA
SM (5M), or 4 ng Alk7-SM (7M) along with 500 pg HA-Smt3C as an internal loading control. α-HA IP-Westerns were performed on stage 10.5 embryos. (B) Embryos
were injected with 1 ng Xnr1, 20 pg ActβB, 2 ng Derrière, 2 ng cDsl-hGDF11, or 2 ng cDsl-mGDF8 along with 3 ng xAlk4-HA S275M (4M) or WT (4W), 50 pg
rAlk5-HA S278M (5M) or WT (5W), or 4 ng rAlk7-HA S270M (7M) or WT (7W). Animal caps were incubated in 100 μM SB-431542 or DMSO until stages 10–
10.5, and subsequently harvested for Western blots against p-Smad2. (C) Constitutively active Alks (Alk4*, Alk5*, and Alk7*) were injected at various doses and
pSmad2 signaling was assessed in animal caps. (D) 5 ng of rAlk5-HA S278M or rAlk5-HAWTwere coinjected with the same concentrations of ligands used in panel
A and p-Smad2 signaling was assayed in SB-431542 or DMSO-treated animal caps. (E) Xenopus embryos were injected with 3 ng Alk5-HA S278M or WT. Embryos
were treated with 100 μM SB-431542 at stage 6 and harvested at stage 10+, or treated at stage 14 and harvested (tailbud region only) at stage 26. For all experiments,
actin was used as a loading control.
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ectopic activation of p-Smad2 upon expression of the
mutant receptor at doses sufficient for rescue, since the
receptor requires other components such as ligands, type II
receptors, and cofactors to signal efficiently. Therefore,
signaling that is restored in inhibitor-treated/receptor-rescued
embryos most likely reflects endogenous signaling patterns.
Several other type I TGF-β receptor inhibitors that function
along the same principles as SB-431542 have recently been
identified in vitro (DaCosta Byfield et al., 2004; Gellibert et
al., 2004; Kim et al., 2004a,b). Our mutant receptors can be
used to test the specificity of these compounds in vivo as
they become available.Determining type I receptor specificity using the inhibitor/
receptor rescue system
A number of activin/nodal ligands play essential roles during
development and disease. It is unclear, however, which type I
receptors these ligands utilize and whether differential usage of
type I receptors might provide a mechanism for specificity in
the responsiveness of different cells or tissues to ligands.
Previous work in mouse and frogs has indicated that Alk4 is
essential for mesoderm induction and gastrulation during early
development (Chang et al., 1997; Gu et al., 1998). The role of
Alk7 is less clear. No phenotype has been reported to date in
Alk7 knockout mice, but a previous study has indicated that
Fig. 9. Alk4 but not Alk7 can rescue signaling during gastrulation (A) Alk4* and Alk7*-injected animal caps were treated with 100 μM SB-431542 and p-Smad2
signaling was assessed by Western blot at stage 10.5. (B) Embryos injected with different amounts of xAlk4-HA or rAlk7-HAwere treated with 100 μM SB-431542 at
stage 6 and harvested for Western blotting at stage 10+. All mRNA levels were equalized to 6 ng total with eGFP. Embryos injected with (C, D) 3 ng xAlk4-HA
S275M, (E, F) 3 ng xAlk4-HAWT, (G, H) 4 ng rAlk7-HA S270M, or (I, J) 4 ng rAlk7-HAWTwere treated as above and photographed at stage 10+. Note rescue of
blastopore lip formation in Alk4 S275M embryo (red arrow in panel B). Embryos are photographed with the vegetal pole showing, dorsal to the upper left.
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Alk7 and activate transcription of target genes (Jornvall et al.,
2004; Reissmann et al., 2001). We find that, in contrast to Alk4,
Alk7 is at best an inefficient mediator of p-Smad2 signaling by
all the ligands tested in our study, and it could not rescue
endogenous signaling at stage 10+ (Figs. 8B and 9). Alk7 may
require different cofactors or ligand modifications not present in
the pre-gastrula embryo to efficiently mediate signaling.
Alternatively, it may be the preferential receptor for a ligand
not tested in our study. Our results are consistent with the mouse
knockout phenotypes in indicating that Alk4 is the primary type
I receptor for activin/nodal signaling during gastrulation.
We also examined the receptor specificity of ligands
known to signal through Smad2 after gastrulation. GDF11 is
required for anterior–posterior patterning in vertebrates, as
well as for other, later functions including neurogenesis
(McPherron et al., 1999; Wu et al., 2003). A related ligand,
GDF8/myostatin, is a negative regulator of muscle mass
(McPherron et al., 1997). Here, we find that both of theseligands, which are active in later development and, at least
in the case of myostatin, throughout adulthood, can signal
through both Alk4/Alk7 and Alk5 (Figs. 8B and D).
Utilization of the inhibitor/receptor rescue system in tissues
in which these ligands are active in vivo will shed light on
the endogenous functions of the various type I receptors in
GDF11/GDF8 signaling. It will be interesting to see whether
the usage of different type I receptors by these ligands in
vivo is spatially or temporally regulated, and whether Alk4
and Alk5 might mediate different downstream activities.
Intriguingly, the only ligands that can signal through Alk5 in
our assay are those that are not expressed during early
development, such as GDF11 and GDF8. Consistent with this
observation, we find that mutant Alk5 cannot rescue p-Smad2
signaling or phenotype during gastrulation, but can rescue
signaling during tailbud stages (Fig. 8F). Alk5 (TβRI) knockout
mice do not display gastrulation defects but later develop
vascular and circulatory abnormalities (Larsson et al., 2001).
Our data are consistent with the mouse knockout phenotype,
741D.M. Ho et al. / Developmental Biology 295 (2006) 730–742indicating that Alk5 is unnecessary for early development and
pattern formation and instead is essential for later patterning.
Using the inhibitor/receptor rescue system to examine the basis
of receptor specificity
Our results suggest that type I receptor specificity and ligand/
receptor pairings may play a role in the regulation of various
TGF-β ligand-mediated processes. Previous work on the basis
of receptor specificity has relied on cell lines that are deficient in
individual Type I receptors. Only a very limited number of such
lines are available, and interpretation of data from these lines is
complicated by the potential presence of other type I receptors
that are functionally redundant with the one that is missing. SB-
431542-resistant receptors provide a simple way to systemat-
ically examine the role of receptor domains in mediating aspects
of TGF−β signaling, as SB-431542 can be used to remove all
background signaling from endogenous receptors in virtually
any cell line, tissue, or embryo, leaving only the mutant receptor
of interest.
There are a number of potential applications of this approach
to the study of context-specific function of Type I receptors.
General regions or specific residues that are important for
interaction of type I receptors with ligands and co-receptors
have been identified (Harrison et al., 2003; Yeo and Whitman,
2001). Detailed structure–function analysis, particularly in a
developmentally relevant context, is difficult in the absence of
cell lines or embryos null for endogenous receptor function. The
inhibitor-resistant receptor approach makes convenient the
inactivation of endogenous receptors by chemical inhibition,
allowing the use of rescue by mutant receptors as a test system
for receptor structure–function studies.
This system should also make more accessible the study of
signaling pathways used by activin/nodal type I receptors. In
addition to signaling through Smads, TGF-β superfamily
ligands can signal through a number of Smad-independent
pathways, including activation of the Erk, JNK, p38 MAPK,
and AKT pathways (Derynck and Zhang, 2003). Mutation of
the L45 loop of Alks separates Smad-dependent from Smad-
independent signaling (Yu et al., 2002); the combination of
mutations in this region with our SB-431542-resistant mutation
makes straightforward the study of Smad-independent signaling
in a background functionally null for endogenous Alk4/5/7
receptors. More generally, the inhibitor-resistant receptors
provide a broad approach to studying receptor mutations in
the absence of endogenous receptor function.
Using the inhibitor/receptor rescue system to examine temporal
and spatial requirements for signaling during development
The inhibitor/receptor rescue system should be useful for the
study of activin/nodal signaling in later development. It is
difficult to assess the late phenotypes of genetic mutants such as
Mzoep and cyc;sqt because of the confounding effects of the
early inhibition of mesendoderm specification. The injected
mRNA that we use here does not persist long enough to allow
for the examination of late defects. Therefore, the generation ofstable transgenic lines carrying the mutant Alks will facilitate
characterization of late defects, since SB-431542 can be
specifically applied later in development.
This system can also be used to examine spatial requirements
and tissue specificity throughout development. For example,
transgenic animals can be generated that express mutant Alks
under tissue-specific or inducible promoters, thus providing a
means of specifically restoring signaling at given times or
places in inhibitor-treated animals. Furthermore, since the
mutant receptors do not ectopically activate signaling in the
manner of constitutively active receptors, their introduction
should not perturb endogenous processes.
The general strategy described here can be used to
generate similar inhibitor/rescue systems for the study of
other signaling pathways in development and disease. With
the advent of high-throughput screening and the availability
of large chemical libraries, pharmacological inhibitors for a
wide range of pathways have become more and more
commonplace. Rigorous proof of inhibitor specificity in
vivo, however, must be demonstrated before these compounds
can be used for therapeutic applications. The pathway-specific
rescue strategy described here can be used to determine the
specificity of a wide range of chemical inhibitors in complex
in vivo systems.
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